Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1390562 | 0.80 | ALDH1A1 (0.37) | KMT2AALDH1A1 | |
| SCHEMBL1390847 | 0.79 | KDM4E (0.46) | KMT2AALDH1A1CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL3451652 | 0.79 | HRH4 (0.39) | LMNAALDH1A1CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL17910665 | 0.77 | KMT2A (0.51) | KMT2ASMN1; SMN2LMNAALDH1A1CYP2C9 | |
| SCHEMBL17910661 | 0.77 | KMT2A (0.51) | KMT2ASMN1; SMN2LMNAALDH1A1CYP2C9 | |
| SCHEMBL9165539 | 0.76 | KMT2A (0.50) | KMT2AIDO1MLKLSMN1; SMN2ALOX12 | |
| SCHEMBL3746821 | 0.76 | POLB (0.59) | KMT2AIDO1MLKLSMN1; SMN2ALOX12 | |
| SCHEMBL9168572 | 0.75 | KMT2A (0.52) | KMT2AIDO1MLKLSMN1; SMN2ALOX12 | |
| SCHEMBL8328219 | 0.75 | KMT2A (0.49) | KMT2AIDO1MLKLSMN1; SMN2ALOX12 | |
| SCHEMBL36603600 | 0.75 | KMT2A (0.61) | KMT2AIDO1MLKLSMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | KMT2A 2667/4885IDO1 131/4885MLKL 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.